While long-acting synthetic somatostatin analogues target the somatostatin receptors (sst), they differ in their binding affinity to these receptors [13], Somatostatin binds with high affinity to all somatostatin receptors, while octreotide is a preferential sst2 ligand, which targets the high levels of somatostatin receptor subtype 2 expressed in colon cancers [13]. Here, SST is linked to malignant colon neoplasm.